

Haematologica  
HAEMATOL/2016/159053  
Version 3

Targeted therapy for a subset of acute myeloid leukemias that lack  
expression of aldehyde dehydrogenase 1A1

Maura Gasparetto, Shanshan Pei, Mohammad Minhajuddin, Nabilah Khan, Daniel A. Pollyea, Jason R. Myers, John M. Ashton, Michael W. Becker, Vasilis Vasiliou, Keith R. Humphries, Craig T. Jordan, and Clayton A. Smith

Disclosures: The disclosures are included here. CS was a founder of Aldagen and one of the developers of Aldefluor®. The other co-authors and I declare no conflicts of interest. My co-authors have all contributed to this manuscript and approve of this submission.

Contributions: MG, SP, performed research, data analysis and contributed on writing the manuscript. MM, NK performed research. VV, KH, provided mice and supervised the study. DP provided patient samples. CT, CS, supervised the study and CS wrote the study. JM, JA and MB provided their RNA-Sequencing data set and additional analyses.